ONO 5334 sustained-release efficacy and pharmacokinetics when administered as single doses of 50, 100 or 300mg in postmenopausal women

Trial Profile

ONO 5334 sustained-release efficacy and pharmacokinetics when administered as single doses of 50, 100 or 300mg in postmenopausal women

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs ONO 5334 (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 14 Oct 2011 New trial record
    • 20 Sep 2011 Results presented for the first part of the study at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top